Additional European Equity News

AstraZeneca (AZN LN) - The CALLA Phase III trial for AstraZeneca’s Imfinzi given concurrently with chemoradiotherapy (CRT) did not achieve statistical significance for the primary endpoint of improving progression-free survival (PFS) versus CRT alone in the treatment of patients with locally advanced cervical cancer. (AstraZeneca)

Krones (KRN GY) - Final FY21 (EUR): Revenue 3.63bln (prelim 3.63bln). EBITDA 312.6mln (prelim. 312.6mln). EBITDA margin +8-9%. (Newswires) 

Next (NXT LN) - FY21 (GBP): pre-tax 823mln (exp. 822.5mln). Co. cuts profit guidance amid the Russia-Ukraine war. Co. is to restart dividend payment and says in the year ahead, it will return to pre-pandemic dividend cycle. EPS +12% Y/Y. (Newswires)

Scout24 (G24 GY) - FY21 (EUR): Revenue 389mln (prev. 353.8mln Y/Y)). EBITDA 222.8mln (prev. 212.3mln); proposes dividend in the upper range of policy. (Newswires) 

Tullow Oil (TLW LN) - Appoints Jonathan Swinney as CFO. (Newswires) 

Nokian (TYRES FH) downgraded to Hold from Buy at Nordea

24 Mar 2022 - 07:40- EquitiesResearch Sheet- Source: Newsquawk

AstraZeneca PLCPharmaceuticals (Group)PharmaceuticalsPharmaceuticals, Biotechnology & Life SciencesUnited KingdomKrones AGTullow Oil PLCEuropean Equity NewsConsumer Discretionary Distribution & RetailNext PLCBroadline RetailBroadline Retail (Group)EquitiesFTSE 100 IndexTLW.LNNXT.LNKRN.GYPFS.USAZN.LNEuropeIIINXT3i Group PLCAsset Management & Custody BanksCapital MarketsFinancial ServicesEURAsian SessionHighlightedResearch SheetGBPAZNNASDAQ 100 Index

Subscribe Now to Newsquawk

Click here for a 1 week free trial

Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include: